Digital apparatus and application for treating mild cognitive impairment and dementia
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11903721-B1
Publication Date
2024-02-20
Expiration Date
Abstract
Methods and apparatuses are described herein for treating a patient with mild cognitive impairment (MCI) or dementia by one or more digital therapeutics. For example, a patient. who has been diagnosed with the MCI or dementia may administer one or more digital therapeutics to the patient to improve a plurality of neurohumoral factors that cause the MCI or the dementia of the patient. The digital therapeutics may include one or more digital instructions that are generated to treat at least one imbalance of the plurality of neurohumoral factors based on at least one neurohumoral change among the plurality of neurohumoral factors by the patient's performance of the one or more digital instructions. The one or more digital instructions may include at least one of an execution environment setting, a lifestyle change, learning, exercising, or affirmation/achievement task.
Core Innovation
The invention relates to digital therapeutics (DTx) and a digital apparatus/application for treating or inhibiting progression of amnestic mild cognitive impairment (MCI) and Alzheimer’s disease (AD). The disclosed approach links dementia risk and progression to neurohumoral factors, including imbalances or changes in sex steroid hormones, insulin-like growth factor-2 (IGF-2), β-catenin in Wnt signaling, Bcl-2-associated athanogene 1 (BAG1), cAMP response element-binding protein (CREB), inflammation factors, corticosteroids, and neurohormones.
The system generates DTx modules that map neurohumoral factors to “imaginary parameters” and to user-facing digital instructions. The imaginary parameters include at least neurogenesis in hippocampus, anti-inflammation, anti-stress, and anti-depression, and the generated instructions include execution environment setting, lifestyle change, new experience, learning/memory tasks, acute exercise, and affirmation/achievement tasks.
The invention includes sensing patient adherence and execution outcomes and using them in iterative feedback loops. Adherence and execution outcomes are sensed and/or self-reported using sensors, and the sensed outcomes are used to generate patient-customized second digital instructions. The system adjusts therapeutic hypotheses/module weights based on the detected neurohumoral change and the adherence, and it can involve a server and roles such as a patient and a doctor prescribing/monitoring while utilizing medical information such as an electronic medical record (EMR) and family history.
Claims Coverage
The partial document includes three independent claims. They center on digital therapeutic instructions that regulate neurohumoral factors in closed-loop fashion using sensor-detected execution outcomes and adherence.
Digital instructions improving neurohumoral factors with sensor-based adherence
Providing one or more first digital instructions to improve one or more neurohumoral factors causing the patient’s MCI or dementia; detecting at least one neurohumoral change among the neurohumoral factors occurring because of the patient’s performance of the first digital instructions; detecting the patient’s adherence to the first digital instructions using a sensor; and generating one or more second digital instructions to treat an imbalance of the neurohumoral factors based on the neurohumoral change and the adherence, wherein the neurohumoral factors comprise at least one of sex steroid hormone, insulin-like growth factor-2 (IGF-2), β-catenin in Wnt signaling, BAG1, CREB, inflammation factors, corticosteroids, or neurohormones.
Module-based neurohumoral regulation using execution outcomes from sensors
Providing one or more first digital instructions to a first user based on at least part of a plurality of digital therapeutic modules configured to regulate one or more neurohumoral factors to treat MCI or dementia, each module comprising one or more first digital instructions for the first user to follow; collecting the first user’s execution outcomes of the first digital instructions using a sensor; and providing one or more second digital instructions to regulate the neurohumoral factors to treat the MCI or the dementia based on the first user’s execution outcomes.
Digital system generating first and second instructions for neurohumoral regulation via sensing
A digital system comprising a processor configured to provide one or more first digital instructions to a first user based on at least part of a plurality of digital therapeutic modules configured to regulate one or more neurohumoral factors to treat MCI or dementia; collect the first user’s execution outcomes of the first digital instructions using a sensor; and provide one or more second digital instructions to regulate the neurohumoral factors to treat the MCI or the dementia based on the first user’s execution outcomes.
Across the independent claims, the core coverage is a digital therapeutic workflow that provides first digital instructions to improve or regulate specified neurohumoral factors for treating MCI or dementia, collects sensor-based execution outcomes and adherence, detects neurohumoral change, and generates second digital instructions based on those sensed outcomes.
Stated Advantages
Documented Applications
Treating or inhibiting progression of amnestic mild cognitive impairment (MCI) and Alzheimer’s disease (AD).
Treating a patient or a subject having mild cognitive impairment (MCI) or dementia using one or more digital therapeutics.
Interested in licensing this patent?